Edwin DeJesus

Summary

Publications

  1. ncbi A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
    Princy N Kumar
    Georgetown University Medical Center, Washington, DC, USA
    AIDS Res Ther 6:3. 2009
  2. ncbi Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Antivir Ther 15:711-20. 2010
  3. ncbi Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida
    J Int Assoc Physicians AIDS Care (Chic) 6:95-100. 2007
  4. ncbi Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL 32803, USA
    J Acquir Immune Defic Syndr 51:163-74. 2009
  5. ncbi Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study
    Edwin DeJesus
    Orlando Immunology Center, 1701 N Mills Avenue, Orlando, FL 32803, USA
    Antimicrob Agents Chemother 52:4315-9. 2008
  6. ncbi A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients
    E Dejesus
    Orlando Immunology Center, Orlando, FL, USA Anthony Mills MD Inc, Los Angeles, CA, USA AIDS Healthcare Foundation, Los Angeles, CA, USA Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA
    Int J Clin Pract 65:1240-9. 2011
  7. ncbi Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    Roberto Ortiz
    Orlando Immunology Center, Orlando, Florida, USA
    AIDS 22:1389-97. 2008
  8. ncbi Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida 32803, USA
    HIV Clin Trials 9:103-14. 2008
  9. ncbi Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects
    Edwin DeJesus
    Orlando Immunology Center, Florida, USA
    Antimicrob Agents Chemother 50:3157-9. 2006
  10. ncbi Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
    Edwin DeJesus
    IDC Research Initiative, Altamonte Springs, FL, USA
    Clin Infect Dis 39:411-8. 2004

Detail Information

Publications11

  1. ncbi A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
    Princy N Kumar
    Georgetown University Medical Center, Washington, DC, USA
    AIDS Res Ther 6:3. 2009
    ..Both regimens offer benefits in select therapy-naïve subjects. TRIAL REGISTRATION: [Clinical Trials Identifier, NCT00082394]...
  2. ncbi Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    Antivir Ther 15:711-20. 2010
    ..A pharmacokinetic trial was conducted to evaluate the potential for once-daily etravirine in antiretroviral regimens without and with darunavir/ritonavir...
  3. ncbi Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida
    J Int Assoc Physicians AIDS Care (Chic) 6:95-100. 2007
    ..Objective: To determine whether dronabinol affects appetite and weight status in patients living with HIV/AIDS...
  4. ncbi Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL 32803, USA
    J Acquir Immune Defic Syndr 51:163-74. 2009
    ....
  5. ncbi Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study
    Edwin DeJesus
    Orlando Immunology Center, 1701 N Mills Avenue, Orlando, FL 32803, USA
    Antimicrob Agents Chemother 52:4315-9. 2008
    ....
  6. ncbi A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients
    E Dejesus
    Orlando Immunology Center, Orlando, FL, USA Anthony Mills MD Inc, Los Angeles, CA, USA AIDS Healthcare Foundation, Los Angeles, CA, USA Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA
    Int J Clin Pract 65:1240-9. 2011
    ..Rates of AEs were similar between the two arms, whereas HDL-C increased and TC:HDL-C decreased significantly more in patients taking NVP than ATV/r...
  7. ncbi Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    Roberto Ortiz
    Orlando Immunology Center, Orlando, Florida, USA
    AIDS 22:1389-97. 2008
    ....
  8. ncbi Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine
    Edwin DeJesus
    Orlando Immunology Center, Orlando, Florida 32803, USA
    HIV Clin Trials 9:103-14. 2008
    ....
  9. ncbi Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects
    Edwin DeJesus
    Orlando Immunology Center, Florida, USA
    Antimicrob Agents Chemother 50:3157-9. 2006
    ..A regimen of 700 mg of FPV BID plus 100 mg of RTV BID may be coadministered with NVP without dose adjustment...
  10. ncbi Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
    Edwin DeJesus
    IDC Research Initiative, Altamonte Springs, FL, USA
    Clin Infect Dis 39:411-8. 2004
    ..Median increase above baseline in CD4(+) cell count was similar (q.d. group, +144 cells/mm(3); b.i.d. group, +146 cells/mm(3)), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable...
  11. ncbi Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    J Acquir Immune Defic Syndr 43:1-5. 2006
    ..CONCLUSIONS: GS-9137 demonstrated substantial short-term antiviral activity and was well tolerated as monotherapy, thus warranting further study...